Vertex Pharmaceuticals Inc (fra:VX1) Share Price

Company Profile

Business description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Contact
50 Northern Avenue
BostonMA02210
USA
T: +1 617 341-6100
E: [email protected]
https://www.vrtx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6,100

Recommended

Investors will get to see if the new strategy and capital management framework are working.

Brian Han | 27 January 2026

These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 27 January 2026

Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.

Sarah Hansen | 26 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,268.50	94.30	1.03%
CAC 40	8,164.45	33.30	0.41%
DAX 40	24,915.71	17.37	-0.07%
Dow JONES (US)	49,412.40	313.69	0.64%
FTSE 100	10,215.04	66.19	0.65%
HKSE	27,126.95	361.43	1.35%
NASDAQ	23,601.36	100.11	0.43%
Nikkei 225	53,333.54	448.29	0.85%
NZX 50 Index	13,510.88	50.14	0.37%
S&P 500	6,950.23	0.00	0.00%
S&P/ASX 200	8,941.60	96.50	1.09%
SSE Composite Index	4,139.90	7.30	0.18%